Straits Times Index
3,111.65 +18.85 (+0.61%) Nikkei
26,491.97 +320.72 (+1.23%) Hang Seng
21,719.06 +445.19 (+2.09%) FTSE 100
7,208.81 +188.36 (+2.68%) BTC-USD
21,305.22 +250.32 (+1.19%) CMC Crypto 200
462.12 +8.22 (+1.81%)
Gilead Sciences, Inc. (GILD)
After hours:
| Previous close | 62.58 |
| Open | 62.81 |
| Bid | 62.71 x 40000 |
| Ask | 63.23 x 1800 |
| Day's range | 61.85 - 63.13 |
| 52-week range | 57.17 - 74.12 |
| Volume | |
| Avg. volume | 8,285,567 |
| Market cap | 79.122B |
| Beta (5Y monthly) | 0.38 |
| PE ratio (TTM) | 17.62 |
| EPS (TTM) | 3.58 |
| Earnings date | 27 Jul 2022 - 01 Aug 2022 |
| Forward dividend & yield | 2.92 (4.67%) |
| Ex-dividend date | 14 Jun 2022 |
| 1y target est | 69.21 |
- Zacks
Gilead (GILD) Announces Positive Data on Hepcludex for HDV
Gilead (GILD) Hepcludex meets the primary endpoint in a phase III study for the treatment of chronic hepatitis delta virus (HDV) infection at 48 weeks.
- Business Wire
Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV
FOSTER CITY, Calif., June 24, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for investigational lenacapavir for the treatment of HIV-1 infection, in combination with other antiretroviral(s), in adults with multi-drug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.
- Motley Fool
2 Beaten-Down Dividend Stocks That Are Now Yielding 5%
Shares of Gilead Sciences (NASDAQ: GILD) and Best Buy (NYSE: BBY) have fallen more than 19% this year. Are these dividend stocks potential steals right now, or should you be worried about a possible cut to their above-average payouts? Gilead's 19% year-to-date decline has actually been modest, compared to the S&P 500, which is down 23% over the same time frame.
